Microsoft Readies New AI Model to Compete With Google, OpenAI - The Information By Investing.com - May 06, 2024 MSFT +0.06%GOOGL -0.19%
Morgan Stanley sees nearly 40% downside risk for Carvana stock By Investing.com - May 06, 2024 CVNA +2.16%
Amazon stock target raised at Loop as retail business still underestimated By Investing.com - May 06, 2024 AMZN +1.40%
Robinhood receives SEC notice about potential action against crypto unit, shares slip By Investing.com - May 06, 2024 HOOD -3.11%
Arthur J. Gallagher Acquires Health Insurance Consultants Australia By Investing.com - May 06, 2024 AJG +0.64%
Synopsys to Sell its Software Integrity Business to Clearlake Capital and Francisco Partners in $2.1B Deal By Investing.com - May 06, 2024 SNPS -0.37%
Bitcoin price today: slips back below $64k after weekend recovery By Investing.com - May 06, 2024 1 DXY -0.23%BTC/USD +0.18%BTC/USD -0.05%XRP/USD -1.86%ETH/USD -0.04%ETH/USD -0.04%SOL/USD +1.09%
TC Biopharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies By Investing.com - May 06, 2024 TCBP -0.81%
Robinhood receives "Wells Notice" from the Staff of the SEC By Investing.com - May 06, 2024 HOOD -3.11%
Dow Jones, Nasdaq, S&P 500 weekly preview: Focus on Disney, Arm earnings reports By Investing.com - May 06, 2024 SP500 +0.24%DJI +0.42%DIS +0.14%NASDAQ +0.12%ARM -4.19%
Stock prices are now at 'more attractive levels' - Oppenheimer By Investing.com - May 06, 2024 SP500 +0.24%DJI +0.42%
Lyra Therapeutics says ENLIGHTEN 1 trial did not meet its primary endpoint By Investing.com - May 06, 2024 LYRA -0.77%
March chip sales above seasonality - Citi By Investing.com - May 06, 2024 MU -0.93%MCHP -0.06%ADI -0.11%AMD -0.73%AVGO -1.51%ON +0.83%
Morgan Stanley warns about an 'uncertain macro backdrop' By Investing.com - May 06, 2024 SP500 +0.24%
Tyson Foods earnings beat by $0.23, revenue fell short of estimates By Investing.com - May 06, 2024 TSN +0.37%
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications By Investing.com - May 06, 2024 GOSS -2.44%